Synthetic cannabinoid toxicity
Novel psychoactive · Toxicology
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Toxicity from synthetic cannabinoid receptor agonists ("spice", "K2") which are far more potent than THC, causing agitation, psychosis, seizures, tachycardia, and sometimes AKI and cardiotoxicity.
Red flags
- Seizures
- Severe agitation/psychosis
- Chest pain / arrhythmia
- AKI / rhabdomyolysis
Assessment
Differential diagnosis
- Sympathomimetic toxicity
- Cannabis intoxication
- Serotonin syndrome
- Primary psychosis
- Anticholinergic toxidrome
Investigations
- Clinical diagnosis (standard cannabis assays do not detect these agents)
- ECG, U&E (AKI reported), CK, glucose
- Consider CT/LP if altered mental status unexplained
- Exclude co-ingestants
Management
- Provide a calm environment; benzodiazepines for agitation, seizures and tachycardia
- IV fluids; monitor for rhabdomyolysis and AKI
- Supportive cardiac monitoring
- Treat hyperthermia with cooling
- Observe until agitation and vital signs settle
Drugs & doses
Benzodiazepines (mainstay for agitation/seizures)
IV isotonic fluids
Antiemetics; active cooling if hyperthermic
Antipsychotics with caution for refractory agitation
Disposition
Observe until settled; admit for seizures, AKI or cardiac features; psychiatry if persistent psychosis.
Complications & pitfalls
- Seizures
- Acute kidney injury
- Rhabdomyolysis
- Cardiac events
- Prolonged psychosis
Exam pearls
- Routine cannabinoid immunoassays are usually negative - diagnosis is clinical.
- Potency and unpredictability far exceed natural cannabis; effects can be severe.
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.